Efavirenz
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
- Efavirenz
- Pharmacist Assessment Report
- Efavirenz: From HIV Infection to Simian Immunodeficiency Virus Infection
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Efavirenz: From HIV Infection to Simian Immunodeficiency Virus Infection
One-Sentence Summary
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) originally used to treat HIV infection and AIDS. The TxGNN model predicts it may be effective for simian immunodeficiency virus infection, but the supporting evidence is 0 clinical trials and 14 publications, almost all animal or laboratory studies. This prediction mostly reflects an animal model of HIV-1 therapy rather than a truly new human indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV infectious disease; AIDS |
| Predicted New Indication | Simian immunodeficiency virus infection |
| TxGNN Prediction Score | 0.9980 |
| Evidence Level | L4 (preclinical and animal studies only; no clinical trials) |
| Canada Market Status | Marketed (marketed DINs: 8 of 8) |
| Number of DINs | 8 (marketed: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, efavirenz is an NNRTI that binds HIV-1 reverse transcriptase (RT) and blocks viral replication. Its efficacy in HIV infection is established.
Wild-type SIV is intrinsically resistant to NNRTIs, so efavirenz would not be expected to work against it. However, the chimeric virus RT-SHIV, which carries HIV-1 RT inside an SIV backbone, is susceptible to efavirenz. In macaques infected with RT-SHIV, efavirenz (alone or in combination with lamivudine and tenofovir) suppressed viral replication. The mechanism is therefore the same as in the approved HIV indication. The “new indication” is essentially a research model for studying HIV-1 therapy, not a new human use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The table shows the most relevant publications. All are animal, in vitro, or mechanistic studies; none is an RCT.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15328115 | 2004 | Animal study | Antimicrob Agents Chemother | Efavirenz therapy evaluated in rhesus macaques infected with RT-SHIV (SIV carrying HIV-1 RT) |
| 15919889 | 2005 | Animal study | J Virol | Efavirenz + lamivudine + tenofovir suppressed virus load in RT-SHIV-infected macaques |
| 24777106 | 2014 | Animal study | Antimicrob Agents Chemother | Four- and five-drug enhanced ART improved viral decay kinetics in macaques |
| 19889213 | 2009 | Animal study | Retrovirology | Viral subpopulation dynamics in macaques given short-course efavirenz then combination ART |
| 22933296 | 2012 | Preclinical | J Virol | Ultrasensitive PCR revealed rare preexisting drug-resistant variants in macaques |
| 21084490 | 2011 | Preclinical | J Virol | Viral genetic diversity persists in macaques despite ART |
| 26559632 | 2015 | Animal study | Retrovirology | Plasma and tissue viral populations were well mixed, suggesting little tissue replication during ART |
| 35856680 | 2022 | Preclinical imaging | Antimicrob Agents Chemother | Imaging of antiretroviral distribution, viral RNA and fibrosis in macaque spleens |
| 15564466 | 2004 | In vitro | J Virol | Characterization of the SIV-HIV RT chimera for studying NNRTI resistance in pigtail macaques |
| 15040537 | 2004 | In vitro | Antivir Ther | Susceptibility of HIV-2, SIV and SHIV to anti-HIV-1 drugs, relevant to treatment and post-exposure prophylaxis |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02389762 | TEVA-EFAVIRENZ | Not listed | Not listed |
| 02381524 | MYLAN-EFAVIRENZ | Not listed | Not listed |
| 02418428 | AURO-EFAVIRENZ | Not listed | Not listed |
| 02468247 | APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR | Not listed | Not listed |
| 02461412 | MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | Not listed | Not listed |
Eight valid single-entity authorizations are listed in total; the five above are shown.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): Related conditions include liver failure, liver disease, fatty liver disease, non-alcoholic steatohepatitis, chronic hepatitis B and C virus infection, kidney disease, Fanconi renotubular syndrome, lactic acidosis, epilepsy, anxiety disorder, delusional disorder, paranoid schizophrenia, hypertriglyceridemia, hypophosphatemia, osteomalacia and rickets.
- Drug Interactions: 100 interactions were identified. One is rated Major: dolasetron. Many are Moderate, including acarbose, famotidine, rabeprazole, bupropion, aprepitant, clarithromycin, pioglitazone, saxagliptin, and the corticosteroids hydrocortisone, dexamethasone, betamethasone and triamcinolone.
Please also refer to the package insert for authoritative warnings.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is supported only by animal and laboratory work using an HIV-1 RT chimeric virus. It reflects an HIV therapy model, not a new human use. No clinical trials exist, and the mechanism is identical to the approved indication.
To proceed, the following is needed:
- A clear research question (for example, use as a preclinical model tool) rather than a clinical repurposing goal
- Detailed mechanism of action data
- Health Canada package insert warnings and contraindications for formal safety screening
- Other predicted indications are weaker: feline acquired immunodeficiency syndrome has only one in vitro structural study (Hold), and the neurodevelopmental disorder prediction has no supporting evidence (Hold)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.